2009

  • Exedral® (Exemestane), another anticancer pharmaceutical product developed internally, successfully passed clinical testing and registration begun in the EU and other countries.
  • Remedica received the Export Award for Industry and under the company’s Corporate Social Responsibility policy, the “Remedica Volunteer” team was formed.
  • A new cardiovascular product, Acapril® (Ramipril) was registered.